Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11985629 | 0.98 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2SIGMAR1TDP1CHRM5 | |
| SCHEMBL24926306 | 0.93 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2SIGMAR1TDP1CHRM5 | |
| SCHEMBL11985634 | 0.88 | SIGMAR1 (0.44) | ALDH1A1SMN1; SMN2SIGMAR1CACNA1HPOLB | |
| SCHEMBL11985636 | 0.86 | KDM4E (0.49) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL24926263 | 0.78 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2SIGMAR1TDP1CACNA1H | |
| SCHEMBL13975161 | 0.78 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2SIGMAR1TDP1CACNA1H | |
| SCHEMBL10101745 | 0.77 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2SIGMAR1TDP1CACNA1H | |
| SCHEMBL24926282 | 0.75 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2SIGMAR1TDP1CACNA1H | |
| SCHEMBL12454178 | 0.75 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2SIGMAR1TDP1CACNA1H | |
| SCHEMBL24926262 | 0.75 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2SIGMAR1TDP1CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | ALDH1A1 3787/4885SMN1; SMN2 2381/4885SIGMAR1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.